Search results for " Nonsense"

showing 4 items of 54 documents

Systematic search for neutropenia should be part of the first screening in patients with poikiloderma.

2011

Poikiloderma occurs in a number of hereditary syndromes, the best known of which is Rothmund-Thomson syndrome (RTS). Differential diagnoses include Dyskeratosis Congenita (DC) with high genetic heterogeneity and Clericuzio-type Poikiloderma with Neutropenia (CPN) due to mutations in the C16orf57 gene. Mutations in the RECQL4 gene are only observed in two thirds of RTS patients. In this study, 10 patients referred for syndromic poikiloderma and negative for RECQL4 sequencing analysis were investigated for C16orf57 mutations. Two C16orf57 heterozygous nonsense mutations (p.W81X and p.Y89X) were identified in a 5-year-old female child presenting with generalized poikiloderma, dental dysplasia,…

medicine.medical_specialtyHeterozygoteNeutropeniaNonsense mutationPoikilodermaNeutropeniaDiagnosis DifferentialGeneticsmedicineHumansAbnormalities MultipleGenetic TestingGenetics (clinical)Genetic testingRetrospective StudiesGeneticsmedicine.diagnostic_testRecQ HelicasesGenetic heterogeneitybusiness.industryRothmund-Thomson SyndromeGeneral Medicinemedicine.diseaseDermatologyPedigreePalmoplantar keratodermaCodon NonsenseChild PreschoolAbsolute neutrophil countErythrocyte CountFemalebusinessDyskeratosis congenitaEuropean journal of medical genetics
researchProduct

OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF GENETIC DISEASES DUE TO NONSENSE MUTATIONS

2018

Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.

oxadiazoles read through promoters TRIDs Cystic Fibrosis genetic diseases nonsense mutations premature termination codons drugs
researchProduct

Identification of a new nonsense mutation (Tyr129Stop) of the SRY gene in a newborn infant with XY sex-reversal.

2004

Point mutations and deletions of SRY gene have been described in several cases of XY gonadal dysgenesis. To date, most of these mutations affect the HMG domain of SRY which plays a central role in DNA binding activity of SRY. We report on a non-mosaic XY sex-reversed newborn girl (completely female external genitalia). The direct sequencing of SRY showed a new nonsense mutation in a codon of SRY gene flanking the 3' end of the HMG domain: a thymine is replaced by a guanine at position +387 in codon 129, resulting in the replacement of the amino acid tyrosine (TAT) by a stop codon (TAG). The new mutation of this patient provides further evidence to support the functional importance of the pu…

sex reversalNonsense mutationMolecular Sequence Datanonsense mutationDisorders of Sex DevelopmentGonadal dysgenesismutation SRY sex-reversal newbornBiologyXY gonadal dysgenesisGeneticsmedicineHumansGenes sryGeneGenetics (clinical)Geneticssex determining region YChromosomes Human YBase SequencePoint mutationInfant NewbornSex reversalSex Determination Processesmedicine.diseaseStop codongonadal dysgenesiTestis determining factorCodon NonsenseFemaleAmerican journal of medical genetics. Part A
researchProduct

PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C.

2011

We investigated the therapeutic potential of the premature termination codon (PTC) readthrough-inducing drug PTC124 in treating the retinal phenotype of Usher syndrome, caused by a nonsense mutation in the USH1C gene. Applications in cell culture, organotypic retina cultures, and mice in vivo revealed significant readthrough and the recovery of protein function. In comparison with other readthrough drugs, namely the clinically approved readthrough-inducing aminoglycoside gentamicin, PTC124 exhibits significant better retinal biocompatibility. Its high readthrough efficiency in combination with excellent biocompatibility makes PTC124 a promising therapeutic agent for PTCs in USH1C, as well a…

virusesUsher syndromeGenetic enhancementNonsense mutationGenetic VectorsCell Cycle ProteinsRetina03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineIn vivootorhinolaryngologic diseasesGeneticsmedicineAnimalsHumansMolecular BiologyCells Cultured030304 developmental biologyAdaptor Proteins Signal TransducingGenetics0303 health sciencesOxadiazolesbusiness.industryfungiAminoglycosideTranslational readthroughmedicine.diseasePhenotype3. Good healthAtalurenMice Inbred C57BLCytoskeletal ProteinsLuminescent ProteinsElectroporationchemistryMicroscopy FluorescenceCodon NonsenseCancer researchMolecular MedicineGentamicinsbusinessUsher Syndromes030217 neurology & neurosurgeryHuman gene therapy
researchProduct